Shares

These Biotech Companies Await FDA Decisions In October

There’s perhaps no greater catalyst for shares of a biotech company than FDA approval of one of its product candidates. Conversely, an unfavorable ruling by the FDA can send shares of a biotech firm plummeting. With the FDA having approved 40 novel drugs so far this year (compared to 27 by this same time last year), today’s article takes a… 

5 Low-Priced, Big-Upside Biotech And Medtech Stocks “For Very Aggressive Accounts”

“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count,” notes the author of today’s article. He proceeds to highlight five low-priced biotech and medtech stocks with significant upside potential to consider for very aggressive accounts. For these five stocks – including a… 

Novavax: Now Or Never?

After being awarded $1.6 billion in funding by the U.S. government as part of its fast-track COVID-19 vaccine program Operation Warp Speed – the largest deal made by the program – shares of Novavax surged 32% in one trading session. On the heels of this surge, do shares of Novavax have more room to run – or is there little… 

After Monster Moves Higher, It May Not Be Too Late To Get In On These Top-Performing Pharmaceutical Stocks

With their shares having surged by more than 484%, 500% and 275%, respectively, the three stocks highlighted in today’s article are three of the best-performing pharmaceutical stocks over the past year – and despite them having already experienced monster moves higher, it may not be too late to get in on these stocks’ gains. For more on these three pharmaceutical… 

Does Disappointment Await Investors In These COVID-19 Treatment And Vaccine Plays?

When it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors… 

Micro-Caps, Mega Gains?

Morgan Stanley’s chief US equity strategist believes that stocks hit their true bottom on March 23rd – and that the current rally could well lead to a true recovery. To prepare for the next bull run, he’s advising clients to buy into small-cap stocks, so today’s article highlights “three micro-cap penny stock companies with super-low entry costs (a dollar per… 

Current Opportunities For Retirees, Investors & More

“Instead of worrying about how far share prices will fall or how widely the coronavirus will spread, think about the opportunities,” advises the author of today’s article, who proceeds to outline four opportunities he sees currently – including an opportunity for retirees who need cash from their homes. For more, CLICK HERE

3 Dividend Payers To Consider For Your Retirement Portfolio

Among the three stocks highlighted in today’s article as being strong candidates for a spot in your retirement portfolio is a stock that seems to possess everything a retiree could possibly want in a stock: a generous dividend, stability, a discounted share price and a respectable rate of earnings growth. For the stock in question – and the two other… 

Why Your Retirement Portfolio Could Benefit From These “Downright Boring” Investments

When it comes to building retirement wealth, the author of today’s article points out that “one of the best strategies is also the simplest: Buy shares in great companies, and hold forever.” “Great”, however, doesn’t necessarily mean flashy and exciting. The author proceeds to highlight three stocks that may be considered rather boring, but which could nonetheless be helpful in… 

Anatomy Of A Trump Tweet: Are There Lasting Effects On The Stocks Trump Targets?

Boeing, Lockheed Martin, and Nordstrom are among the companies that have been targets of a President Trump Twitter attack, and the share prices of the companies Trump goes after almost always drop in the immediate aftermath. But are there lasting effects? Today’s article looks at what the Wall Street Journal’s “Trump Target Index” – which tracks the post-attack performance of…